Association of Peroxisome Proliferator-Activated Receptor-δ with Metabolic Syndrome and Atherosclerosis

Yang-Feng Wu
2008-01-01
Abstract:There is an urgent need for pharmacological interventions to diminish diabetic and cardiovascular complications of metabolic syndrome.Synthetic agonists of peroxisome proliferator-activated receptor(PPAR)-δ have shown a promising pharmacological profile in animal and preclinical models of metabolic and cardiovascular disease,which includes increasing HDL-C,fatty acid oxidation,protection from obesity,enhancing insulin sensitivity,repressing inflammation and potential antiatherogenic action.
What problem does this paper attempt to address?